Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 12853

1.

Adjuvant ovarian suppression in premenopausal breast cancer.

Montemurro F, Perrone F, Geuna E.

N Engl J Med. 2015 Apr 23;372(17):1672-3. doi: 10.1056/NEJMc1502618#SA1. No abstract available.

PMID:
25901438
2.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF.

N Engl J Med. 2015 Apr 23;372(17):1673. doi: 10.1056/NEJMc1502618. No abstract available.

3.

Breast cancer prevention in the era of precision medicine.

Narod SA.

J Natl Cancer Inst. 2015 Apr 8;107(5). pii: djv078. doi: 10.1093/jnci/djv078. Print 2015 May. No abstract available.

PMID:
25855708
4.

[Use of herbal medicine for cancer treatment-related toxicities].

Samuels N, Morag O, Maimon Y.

Harefuah. 2015 Jan;154(1):43-6, 67. Hebrew.

PMID:
25796675
5.

[Sentinel lymph node biopsy in male breast cancer - a case report].

Nishi T, Nishimura A, Morohashi S, Hakamada K.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1972-4. Japanese.

PMID:
25731393
6.

[Long-term control of stage IV breast and gastric cancer with combination therapy of S-1 and paclitaxel].

Yamada C, Ishikawa F, Nitta H, Fujita Y, Omoto H, Kamata S, Ito H.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1960-1. Japanese.

PMID:
25731389
7.

[A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].

Kawai H, Sugimoto R, Miyauchi S, Yoshida R, Waki N, Hirayama S, Ishizaki M, Nishi H, Yamashita K.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1957-9. Japanese.

PMID:
25731388
8.

[A case of hyoid bone metastasis from breast cancer].

Kusama H, Okishiro M, Ishida T, Sato Y, Morimoto Y, Matsushita K, Hashimoto T, Kimura K, Katsura Y, Nitta K, Kagawa Y, Takeno A, Sakisaka H, Nakahira S, Taniguchi K, Egawa C, Takeda Y, Kato T, Tamura S, Takatsuka Y, Oku K, Goto T, Nagano T, Nakatsuka S.

Gan To Kagaku Ryoho. 2014 Nov;41(12):1915-7. Japanese.

PMID:
25731374
9.

Twenty-five years of breast cancer risk models and their applications.

Gail MH.

J Natl Cancer Inst. 2015 Feb 26;107(5). pii: djv042. doi: 10.1093/jnci/djv042. Print 2015 May. No abstract available.

PMID:
25722355
10.

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR.

Cancer Treat Rev. 2015 Mar;41(3):271-6. doi: 10.1016/j.ctrv.2015.02.004. Epub 2015 Feb 11. Review.

PMID:
25698635
11.

Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.

Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL.

J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju425. doi: 10.1093/jnci/dju425. Print 2015 Mar.

PMID:
25663687
12.

Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.

Thewes V, Simon R, Schroeter P, Schlotter M, Anzeneder T, Büttner R, Benes V, Sauter G, Burwinkel B, Nicholson RI, Sinn HP, Schneeweiss A, Deuschle U, Zapatka M, Heck S, Lichter P.

Cancer Res. 2015 Feb 15;75(4):720-31. doi: 10.1158/0008-5472.CAN-14-0652. Epub 2015 Feb 2.

PMID:
25643697
13.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

Johnson JA, Hamadeh IS, Langaee TY.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju437. doi: 10.1093/jnci/dju437. Print 2015 Feb. No abstract available.

PMID:
25638249
14.

HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations.

Cuello-Carrión FD, Shortrede JE, Alvarez-Olmedo D, Cayado-Gutiérrez N, Castro GN, Zoppino FC, Guerrero M, Martinis E, Wuilloud R, Gómez NN, Biaggio V, Orozco J, Gago FE, Ciocca LA, Fanelli MA, Ciocca DR.

Clin Exp Metastasis. 2015 Feb;32(2):151-68. doi: 10.1007/s10585-015-9694-5. Epub 2015 Feb 1.

PMID:
25636904
15.

Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

Binkhorst L, Mathijssen RH, Jager A, van Gelder T.

Cancer Treat Rev. 2015 Mar;41(3):289-99. doi: 10.1016/j.ctrv.2015.01.002. Epub 2015 Jan 14. Review.

PMID:
25618289
16.

RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J.

J Clin Oncol. 2015 Mar 1;33(7):709-15. doi: 10.1200/JCO.2014.57.9029. Epub 2015 Jan 20.

PMID:
25605856
17.

Müllerian adenosarcoma: a review of cases and literature.

Huang PS, Chang WC, Huang SC.

Eur J Gynaecol Oncol. 2014;35(6):617-20. Review.

PMID:
25556263
18.

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE.

J Clin Oncol. 2015 Jan 20;33(3):265-71. doi: 10.1200/JCO.2014.57.6926. Epub 2014 Dec 15.

PMID:
25512454
19.

IBIS-I tamoxifen update: maturity brings questions.

Chlebowski RT.

Lancet Oncol. 2015 Jan;16(1):7-9. doi: 10.1016/S1470-2045(14)71184-2. Epub 2014 Dec 11. No abstract available.

20.

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF; IBIS-I Investigators.

Lancet Oncol. 2015 Jan;16(1):67-75. doi: 10.1016/S1470-2045(14)71171-4. Epub 2014 Dec 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk